Status:
RECRUITING
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
Lead Sponsor:
PERROD Guillaume
Conditions:
Lynch Syndrome
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Lynch syndrome (LS) is the most common genetic predisposition syndrome for colorectal cancer (CRC), responsible for around 2-4% of cancers. It is characterized by a pathogenic germline mutation in one...
Eligibility Criteria
Inclusion
- Confirmed pathogenic mutation (path\_MLH1, path\_MSH2, path\_MSH6, path\_PMS2, path\_EpCAM)
- Male or female of legal age at time of colonoscopy prescription.
- Patient agreeing to participate in the study
- Person affiliated with or benefiting from a social security scheme
- Free, informed and express consent
Exclusion
- Patient undergoing total colectomy with ileoanal or ileosigmoid anastomosis
- Patient with a history of Crohn's disease or ulcerative colitis
- Patients with a known allergy or intolerance to polyethylene glycol and ascorbic acid.
- Patients unable to undergo fractionated colonic preparation
- Inadequate colonic preparation: Boston sub-score \<2 per segment
- Patient under guardianship or protected person
- Patient who does not understand French or cannot read
- Person not affiliated to a Social Security system.
- Pregnant women
Key Trial Info
Start Date :
April 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 18 2026
Estimated Enrollment :
272 Patients enrolled
Trial Details
Trial ID
NCT05963191
Start Date
April 18 2024
End Date
April 18 2026
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Européen Georges-Pompidou HEGP
Paris, France, 75015